US payer budget impact of a microarray assay with machine learning to evaluate kidney transplant rejection in for-cause biopsies US payer budget impact of a microarray assay with machine learning to evaluate kidney transplant rejection in for-cause biopsies

By: Christopher Lawrence A US payer budget model demonstrates that MMDx Kidney is a cost-effective intervention despite the cost of the assay and the higher treatment costs associated with identifying more rejection. The authors (including Dr. Chris Lawrence, Sr. Director, Business Development and Medical Affairs) present a budget impact model to estimate the economic impact to a US commercial payer of histology with MMDx Kidney compared to histology alone. In the base case scenario, the model..